Imaging of brain tumor proliferative activity with iodine-131- iododeoxyuridine Journal Article


Authors: Tjuvajev, J. G.; Macapinlac, H. A.; Daghighian, F.; Scott, A. M.; Ginos, J. Z.; Finn, R. D.; Kothari, P.; Desai, R.; Zhang, J.; Beattie, B.; Graham, M.; Larson, S. M.; Blasberg, R. G.
Article Title: Imaging of brain tumor proliferative activity with iodine-131- iododeoxyuridine
Abstract: Methods: Iodine-131-iododeoxyuridine (IUdR) uptake and retention was imaged with SPECT at 2 and 24 hr after administering a 10-mCi dose to six patients with primary brain tumors. The SPECT images were directly compared to gadolinium contrast-enhanced MR images as well as to [18F]fluorodeoxyglucose (FDG) PET scans and 201Tl SPECT scans. Results: Localized uptake and retention of IUdR-derived radioactivity was observed in five of six patients. The plasma half-life of [131I]IUdR was short (1.6 min) in comparison to the half-life of total plasma radioactivity (6.4 hr). The pattern of [131I]IUdR-derived radioactivity was markedly different in the 2-hr compared to 24-hr images. Radioactivity was localized along the periphery of the tumor and extended beyond the margin of tumor identified by contrast enhancement on MRI. The estimated levels of tumor radioactivity at 24 hr, based on semiquantitative phantom studies, ranged between <0.1 and 0.2 μCi/cc (<0.001% and 0.002% dose/cc); brain levels were not measurable. Conclusions: Iodine-131-IUdR SPECT imaging of brain tumor proliferation has low (marginal) sensitivity due to low count rates and can detect only the most active regions of tumor growth. Imaging at 24 hr represents a washout strategy to reduce 131I-labeled metabolites contributing to background activity in the tumors, and is more likely to show the pattern of [131I]IUdR-DNA incorporation and thereby increase image specificity. Iodine-123-IUdR SPECT imaging at 12 hr and the use of [124I]IUdR and PET will improve count acquisition and image quality.
Keywords: adult; clinical article; comparative study; nuclear magnetic resonance imaging; positron emission tomography; brain tumor; brain neoplasms; magnetic resonance imaging; dna synthesis; iodine 131; iodine radioisotopes; pilot projects; contrast enhancement; image quality; fluorodeoxyglucose f 18; iodine 124; tumor growth; gadolinium pentetate; single photon emission computer tomography; pet; fluorodeoxyglucose; thallium 201; intravenous drug administration; oral drug administration; tomography, emission-computed; brain tumors; tomography, emission-computed, single-photon; spect; middle age; iodide; potassium iodide; plasma half life; iodine 123; uracil derivative; idoxuridine; human; male; female; priority journal; article; support, u.s. gov't, non-p.h.s.; iododeoxyuridine; thallium-201-chloride
Journal Title: Journal of Nuclear Medicine
Volume: 35
Issue: 9
ISSN: 0161-5505
Publisher: Society of Nuclear Medicine  
Date Published: 1994-09-01
Start Page: 1407
End Page: 1417
Language: English
PROVIDER: scopus
PUBMED: 8071684
DOI/URL:
Notes: Export Date: 14 January 2019 -- Article -- Source: Scopus
Citation Impact
MSK Authors
  1. Juri Gelovani
    125 Gelovani
  2. Paresh J Kothari
    11 Kothari
  3. Ronald G Blasberg
    272 Blasberg
  4. Ronald D Finn
    279 Finn
  5. Steven M Larson
    959 Larson
  6. Bradley Beattie
    131 Beattie
  7. Martin C Graham
    53 Graham
  8. Jiaju   Zhang
    34 Zhang
  9. Andrew M. Scott
    62 Scott
  10. James Z. Ginos
    15 Ginos